Combination analyses (Table 4 & Table B in S1 File) revealed that RAN rs14035 CT heterozygotes and XPO5 rs11077 AA carriers experienced reduced susceptibility of CRC (AOR = 0.610; 95% CI, 0.434–0.859; P = 0.005) (Table 4). Here, XPO5 is linked to colorectal carcinoma.